



**Karolinska  
Institutet**

This is an author produced version of a paper published by **Journal of Clinical Endocrinology and Metabolism**. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

**Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency : a Swedish population-based national cohort study. J Clin Endocrinol Metab. 2015 Sep;100(9):3520-8.**

**Falhammar, H.; Frisé, L.; Linden Hirschberg, A.; Norrby, C.; Almqvist, C.; Nordenskjöld, A.; Nordenström, A.**

**DOI: [10.1210/JC.2015-2093](https://doi.org/10.1210/JC.2015-2093)**

Access to the published version may require subscription.  
Published with permission from: **Endocrine Society**

1       **Increased cardiovascular and metabolic morbidity in patients with 21-**  
2       **hydroxylase deficiency: a Swedish population-based national cohort study**

3  
4       Henrik Falhammar<sup>1,2</sup>, Louise Frisé<sup>3,4</sup>, Angelica Linden Hirschberg<sup>5,6</sup>, Christina Norrby<sup>7</sup>, Catarina  
5       Almqvist<sup>7,8</sup>, Agneta Nordenskjöld<sup>6,9,10</sup>, and Anna Nordenström<sup>6,11</sup>  
6

7       <sup>1</sup>Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm,  
8       Sweden; <sup>2</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;  
9       <sup>3</sup>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; <sup>4</sup>Child and  
10      Adolescent Psychiatry Research Center, Stockholm, Sweden; <sup>5</sup>Department of Obstetrics and  
11      Gynaecology, Karolinska University Hospital, Stockholm, Sweden; <sup>6</sup>Department of Women's and  
12      Children's Health, Karolinska Institutet, Stockholm, Sweden; <sup>7</sup>Department of Medical Epidemiology  
13      and Biostatistics, Karolinska Institutet, Stockholm, Sweden; <sup>8</sup>Lung and Allergy Unit, Astrid Lindgren  
14      Children's Hospital, Karolinska University Hospital, <sup>9</sup>Center for Molecular Medicine, Karolinska  
15      Institutet, Stockholm, Sweden; <sup>10</sup>Paediatric Surgery, Astrid Lindgren Children Hospital, Karolinska  
16      University Hospital, Stockholm, Sweden; <sup>11</sup>Department of Paediatric Endocrinology, Astrid Lindgren  
17      Children Hospital, Karolinska University Hospital, Stockholm, Sweden

18      **Abbreviated title:** Cardiovascular and Metabolic morbidity in CAH

19      **Key words:** obesity, diabetes, hypertension, venous thromboembolism, glucocorticoid

20      **Counts:** Abstract word count: 250; Main text word count: 3443; References: 31; Tables: 5;  
21      Supplemental Tables: 3.

22      **Corresponding author:** Associate Professor Henrik Falhammar, MD, PhD, Department of  
23      Endocrinology, Metabolism and Diabetes, D02:04, Karolinska University Hospital. SE-171 76  
24      Stockholm, Sweden. E-mail: [henrik.falhammar@ki.se](mailto:henrik.falhammar@ki.se) Phone: +46-851776411, Fax: +46851773096

25      **Grants:** This project was supported by grants from the Magn. Bergvalls Foundation, Karolinska  
26      Institutet, Stockholm County Council and the Swedish Research Council through the Swedish

- 27 Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework grant
- 28 no. 340-2013-5867.
- 29 **Disclosure Summary:** The authors have nothing to disclose.

30 **Abstract**

31 **Context:** Congenital adrenal hyperplasia (CAH) is lethal in its most severe forms if not treated with  
32 glucocorticoids. However, glucocorticoids may increase the risk of cardiovascular and metabolic  
33 morbidity.

34 **Objective:** To study cardiovascular and metabolic morbidity in CAH.

35 **Design, Setting and Participants:** Patients with CAH due to 21-hydroxylase deficiency (n=588;  
36 >80% with known *CYP21A2* mutations) were compared with controls matched for sex, year, and place  
37 of birth (n=58,800). Data were obtained by linking national population-based registers. Subgroup  
38 analyses were performed regarding sex, clinical severity (salt-wasting, simple virilising, nonclassic),  
39 *CYP21A2* genotype (null, I2 splice, I172N, P30L), and stratified by the introduction of neonatal  
40 screening, age-groups, and non-obesity.

41 **Main Outcome Measures:** Cardiovascular and metabolic morbidity.

42 **Results:** In CAH, both any cardiovascular and metabolic disorders (OR 3.9, 95%CI 3.1-5.0), and  
43 cardiovascular disease (OR 2.7, 95%CI 1.9-3.9) were increased. Separate analyses of the individual  
44 diseases showed higher frequencies in CAH of hypertension, hyperlipidemia, atrial fibrillation, venous  
45 thromboembolism, obesity, diabetes (mainly type 2), obstructive sleep disorder, thyrotoxicosis and  
46 hypothyroidism. Similar results were seen in the stratified groups. On the subgroup level, females  
47 were generally more affected (especially I172N and the nonclassic group), as were males with the null  
48 genotype.

49 **Conclusions:** CAH was associated with excess cardiovascular and metabolic morbidity but the  
50 mechanism is not certain as the glucocorticoids were not assessed. Hypothyroidism and obesity may  
51 be an effect of close observation. However, more severe conditions were presumably detected equally  
52 in patients and controls. Screening for diabetes and other metabolic disorders which increase  
53 cardiovascular risk is important.

54 **Introduction**

55 Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder. The most common cause,  
56 21-hydroxylase deficiency, is characterised by a reduction of cortisol and aldosterone production and  
57 concurrently by increased levels of steroid precursors and adrenal androgens (1-3). There is a wide  
58 spectrum of severity of the disease. Untreated CAH is fatal in severe cases due to salt-wasting crises.  
59 Women with classic CAH, i.e., the salt-wasting (SW) or simple virilizing (SV) phenotype, have  
60 varying degrees of virilization of the external genitalia at birth. Individuals with nonclassic (NC) CAH  
61 do not present with cortisol deficiency and may never be diagnosed. If NCCAH is diagnosed, it is  
62 generally due to symptoms and signs of androgen excess, including infertility; therefore, usually more  
63 females rather than males are diagnosed (1, 3).

64 In most cases, glucocorticoid replacement therapy is necessary for survival in classic CAH.  
65 However, the physiological circadian rhythm of cortisol cannot be mimicked with oral  
66 glucocorticoids, and the doses needed to suppress the androgens are usually higher than normal  
67 replacement (3). Hence, the treatment can be expected to be potentially harmful and may result in an  
68 increased risk of obesity, type 2 diabetes, hyperlipidemia and hypertension, i.e., the metabolic  
69 syndrome, resulting in cardiovascular morbidity and mortality. So far, neither increased cardiovascular  
70 morbidity nor an increased prevalence of type 2 diabetes has been found in CAH patients in the few  
71 studies reporting on cardiovascular morbidity (4, 5). This is to be expected since glucocorticoids were  
72 introduced in the 1950s and very few of the studied patients have been over 50 years of age (3).  
73 However, risk factors for cardiovascular disease and an increased risk for metabolic disorders have  
74 been reported in both children and adults (6-11). We have previously reported an increased risk for  
75 gestational diabetes, a strong risk factor for future type 2 diabetes, in women with CAH (4, 12). In  
76 contrast, we could not demonstrate a significant increase in cardiovascular mortality in CAH  
77 individuals compared to controls (13). Thyroid disease can increase both cardiovascular and metabolic  
78 morbidity (14), but it has not been studied in CAH individuals.

79 The aims of this study were to investigate the cardiovascular and metabolic morbidity in a  
80 large population-based national cohort of patients with CAH due to 21-hydroxylase deficiency and to

81 analyze whether the outcomes varied between the different pheno- and genotype groups, or between  
82 the sexes, as well as stratified by the introduction of neonatal screening, age-groups, and non-obesity.

83

## 84 **Methods**

### 85 **Subjects**

86 CAH patients with 21-hydroxylase deficiency and a complete personal identity number born between  
87 1910 and 2009 were identified (n=545) using the national CAH register (15). More than 80% had the  
88 diagnosis genetically confirmed by *CYP21A2* mutation analysis. An additional 43 individuals were  
89 included who had received the diagnosis CAH at least three times in the National Patient Register  
90 (NPR) using the International Classification of Diseases, ICD-8 (255.01, 255.08), ICD-9 (255.2, 255.3) and  
91 ICD-10 (E25.0) and had not subsequently been given other diagnoses, i.e., Addison's disease,  
92 Cushing's syndrome, acromegaly, or received glucocorticoid treatment due to malignancies.

93 Most patients with known *CYP21A2* mutations, analysed as previously described (15, 16),  
94 were allocated to one of the five most prevalent genotype groups (see below). All the different  
95 mutations in this cohort have been described in detail elsewhere (15). The mildest mutation defines the  
96 genotype group in compound heterozygotes. Generally speaking, null and I2 splice are associated with  
97 the SW phenotype, I172N with SV, and V281L with NC. P30L results in a phenotype between SV and  
98 NC, but in this study it was defined as SV. Patients with unknown *CYP21A2* mutations were given a  
99 clinical classification (SW, SV or NC) if clinical data that clearly could be used for classification were  
100 accessible. Genetically verified or clinically diagnosed NC disease was combined to the NC group.  
101 The data were also stratified after the introduction of neonatal screening for CAH in Sweden (1986),  
102 three different age groups (0-19, 20-39, and older than 40 years old), and non-obesity.

103

### 104 **Characteristics of the included patients and controls**

105 All CAH patients (n=588, females n=335) had been diagnosed with 21-hydroxylase deficiency. The  
106 median age was 26.0 (range 0–92) years. The clinical phenotype could be determined in 482 patients

107 (82.0%). SW, SV and NC phenotypes were diagnosed in 240 (20.7 years, range 0-69), 167 (27.4 years,  
108 range 0.4-79), and 75 (22.1 years, range 3.3-92) patients, respectively. In the most common genotype  
109 groups, the numbers were: null, n=100 (19.4 years, range 0.1-57); I2 splice, n=122 (20.6 years, range  
110 0-69); I172N, n=130 (26.9 years, range 0.7-79); P30L, n=24 (22.4 years, range 0.4-38); and V281L,  
111 n=56 (42 females). A similar number of patients were born before and after the introduction of the  
112 neonatal screening programme, but those born before it were older (before, n=305, 40.3 [15-95] years,  
113 178 females; after, n=283, 14.8 [0-24] years, 157 females). Controls matched for sex, year and place  
114 of birth were included from the Total Population Register (n=58,800). The characteristics of this  
115 cohort have been reported previously (13, 17, 18).

116

### 117 **Study protocol**

118 A matched cohort design was employed, with exposure defined as having the diagnosis CAH in the  
119 national CAH Register or in the NPR. Controls matched for birth year, sex and place of birth were  
120 identified in the Total Population Register (100 controls per CAH individual). The Migration Register  
121 (Statistics Sweden), with all migrations since 1901, was used to control for migration. The Swedish  
122 personal identity number enables unambiguous linkage between population-based registers, including  
123 the NPR (maintained by the Swedish Board of Health and Welfare). All participants in this study were  
124 given an anonymous code number by Statistics Sweden after linkage with the registers. The NPR  
125 contains the discharge diagnoses according to the ICD for both in- and outpatient care since 1964 and  
126 2001, respectively. The outcomes were a diagnosis of cardiovascular or metabolic disorders. The  
127 different ICD codes (Swedish version) used for the separate analyses are shown in Table 1. The study  
128 was approved by the Regional Ethical Review Board in Stockholm, Sweden.

129

### 130 **Statistical analysis**

131 A conditional logistic regression model was used to estimate the association between CAH and the  
132 outcomes in Table 1. The same outcomes were also estimated for the different subgroups. Odds ratios

133 (ORs) were calculated with 95% confidence intervals (CIs). A CI not surpassing 1.0 was considered  
134 significant. SAS (version 9.4) was used for all statistical analyses.

135

## 136 **Results**

### 137 **Cardiovascular and metabolic disorders**

138 The results are shown in detail for the total cohort and for males and females in Table 2, broken down  
139 by phenotype group in Table 3 and *CYP21A2* genotype group in Table 4 and the number of patients in  
140 each group is shown in Supplemental Table 1.

141 Any cardiovascular and metabolic disorders were increased in CAH patients, with OR  
142 3.9(3.1–5.0) for the whole cohort, 4.4(3.2–6.0) for females and 3.3(2.3–4.9) for males. The increase  
143 remained significant on the subgroup level for SW (both genders), SV (females), NC (both genders),  
144 null (males), I172N (females) and P30L (males). For cardiovascular disease, the ORs were 2.7(1.9–  
145 3.9) for the total CAH cohort and 3.9(2.5–6.1) for females, but were not significant for the males.  
146 They remained significant on the subgroup level for SW (males), SV and NC (females), null (males),  
147 and I172N (females).

148 Obesity was increased in both genders (OR 10-15[5.5–19.5]) and in all subgroups of patients,  
149 except in I2 splice males and P30L females. Obesity was most pronounced in the NC group (both  
150 genders) and the P30L males. Obstructive sleep apnoea was increased in the entire group (OR 2.0[1.0–  
151 4.1]) and in the SV group. In the P30L male group, it almost reached significance. More obese CAH  
152 patients had cardiovascular disease than the non-obese CAH patients (16.3% vs 4.0%, OR 4.6 [1.9–  
153 11.5]). Two thirds of the obese CAH patients had uncomplicated obesity and no other cardiovascular  
154 or metabolic disorders. Three CAH patients (one SW, one NC and one with unknown pheno/genotype)  
155 had obesity and five other cardiovascular and metabolic disorders, including type 2 diabetes,  
156 hypertension, and acute coronary syndrome or stroke. One CAH patient had obesity combined with  
157 hypertension and hypothyroidism while five had obesity combined with hypertension,  
158 hyperlipidaemia, or venous thromboembolism. The obese patients with CAH are described in detail in



159 Supplemental Table 2. Moreover, if only the non-obese CAH patients were compared to their non-  
160 obese controls the results were similar to the entire cohort (Table 7).

161 Diabetes was more prevalent in the entire cohort and among females (OR 3.0[1.6-5.8] and  
162 4.0[1.8–9.1], respectively) compared to controls. The rate in the subgroups was elevated among  
163 females in the SV, NC and I172N groups.

164 Hypertension occurred more often in females (OR 4.1[2.4–7.3]) and remained significant only  
165 for SV and I172N females. The rate of hyperlipidaemia was increased in the total cohort (OR 2.8[1.2–  
166 6.5]) and in the SW and null (males) subgroups. The frequency of stroke was elevated in only the NC  
167 female group.

168 Venous thromboembolic events were raised in the entire cohort (OR 3.8 [1.6–8.7]) and SW,  
169 NC, null and I2 splice subgroups. Mostly CAH females were affected.

170 Acute coronary syndrome was only increased in SW (males) and null (males) groups. Cardiac  
171 arrest and heart failure were similar to the findings in controls in all groups. Atrial fibrillation was  
172 more frequent in the total cohort (OR 2.3[1.0–5.2]), but was not significant at the subgroup level,  
173 except in I172N males. The prevalence of heart block and aortic valve disease was similar to that in  
174 controls. One case of cardiomyopathy (SW female, null genotype) and one case of pulmonary heart  
175 disease (SW female), but no cases of aortic aneurysm and dissection were found in the CAH cohort  
176 (all non-significant compared to controls).

177 Thyroid disease was increased in both males and females. Thyrotoxicosis and hypothyroidism  
178 were increased (OR 4.7[2.4–8.9] and 3.7[2.2–6.3]), being most pronounced in males (OR 15.8[4.7–  
179 53.4] and 12.9[5.8–28.7]). In a subgroup analysis, thyrotoxicosis was more frequent in SW (males),  
180 NC (both genders) and null (males) subgroups. In the subgroup of hypothyroidism only males in SW,  
181 SV, NC, null and I172N groups were affected.

182 Patients born before the introduction of neonatal screening showed similar results to those in  
183 the entire cohort (data not shown), but those born after 1986, showed an increased frequency of any  
184 cardiovascular and metabolic disorders, obesity, hypertension and thyrotoxicosis (data not shown).

185 Compared to controls, those born after the introduction of neonatal screening had higher risk (0.34%  
186 vs 0.04%, OR 7.5[1.7–32.9]) of having hypertension compared to those born before (3.6% vs 1.8%,  
187 OR 1.5[1.0–2.4]). Moreover, when the cohort was stratified into different age groups, the CAH  
188 patients in 0-19 year-old group were mainly affected by obesity and thyrotoxicosis, but females had  
189 more hypertension and males hypothyroidism compared to controls. The older groups of CAH patients  
190 also had more cardiovascular disease compared to controls (Table 5).

191

## 192 **Discussion**

193 This is the first time established cardiovascular disease, and not merely risk factors, have been  
194 investigated in a large cohort of CAH patients. We found increased cardiovascular and metabolic  
195 morbidity in CAH patients compared to controls with some subgroups being more affected than others  
196 (females generally, and specifically I172N and NC, and males in the null genotype group). Obesity  
197 was consistently increased in all subgroups with the NC group and P30L males being most affected.

198 Even though all the separate measured outcomes, except aortic aneurysm, were increased in  
199 CAH individuals, some did not reach statistical significance, probably owing to a lack of statistical  
200 power. Although this is the largest CAH cohort ever reported, the median age was relatively low and  
201 cardiovascular disease occurs more commonly at an older age. Moreover, in the general population,  
202 cardiovascular disease is more prevalent in males, which has been attributed to the higher testosterone  
203 levels compared to females. CAH results in elevated androgens, and it could be speculated that this is  
204 one of the reasons for the increased cardiovascular morbidity demonstrated in this study, illustrated by  
205 the NC group being especially affected. Delayed diagnosis, which is frequently seen in the milder  
206 pheno- and genotypes and especially before the introduction of neonatal screening, is frequent and  
207 results in prolonged hyperandrogenism. However, once treatment with glucocorticoids has been  
208 initiated, androgens are usually decreased compared to controls (4, 19).

209 Obesity was markedly increased, which is consistent with many studies reporting an increased  
210 body mass index and/or fat mass in CAH children and adults (4, 5, 8, 11, 20-24). NC individuals and

211 P30L males were most affected by obesity. However, only a minority of the obese CAH patients had  
212 been diagnosed with another cardiovascular or metabolic disorder and the non-obese CAH patients  
213 were similarly affected as the entire CAH cohort. Obstructive sleep apnoea is prevalent in obesity, but  
214 it has only been reported once in a case of CAH (25), although it could be suspected to occur more  
215 frequently. However, we did find an increased frequency of obstructive sleep apnoea in this CAH  
216 cohort. Similarly, the frequency of diabetes was increased, especially in females with SV (I172N  
217 genotype) or NC phenotype. Decreased insulin sensitivity in CAH children and adults has been  
218 reported several times previously (4-6, 9, 23, 26); however, this is the first time a raised occurrence of  
219 diabetes has been found. Interestingly, Williams *et al.* reported insulin resistance only in NC but not in  
220 classic CAH children (26), and in a Chinese study on newly diagnosed and untreated young adult  
221 females with SV, insulin resistance was found. It has also been claimed that androgens in females can  
222 result in insulin resistance (27). Thus, all this taken together could suggest that prolonged postnatal  
223 hyperandrogenism, and not only supraphysiological glucocorticoid replacement therapy together with  
224 obesity, may cause insulin resistance and diabetes in CAH patients. The doses of corticosteroids used  
225 are usually similar in the different pheno- and genotypes (5, 19, 28), and it can be speculated that a  
226 more unfavourable profile could be explained by a relative overtreatment considering the milder  
227 disease. However, doses of corticosteroids are usually those reported only at the time of the study and  
228 the cumulative dose during the entire treatment period is generally unknown. As CAH females have  
229 more symptoms of hyperandrogenism compared to CAH males, the females may have been exposed  
230 to higher doses of corticosteroids, especially during younger ages, which may explain why females  
231 were more affected.

232 An increased rate of hyperlipidaemia was found, especially in our males with null genotype.  
233 Hyperlipidaemia in CAH individuals has been reported in some studies (8, 22), yet, most have found  
234 similar lipid profiles, compared to controls (4-6, 11, 26, 29). We found an increased frequency of  
235 hypertension in CAH individuals, which is similar to other studies (8, 11, 22, 26, 29), but on analysing  
236 the different subgroups, only SV (I172N) females and NC females (tendency) had increased blood  
237 pressures, while this was rare or non-existent in the more severe pheno- and genotypes. Most previous  
238 studies have not compared the results in different pheno-and genotypes; however, a few have indicated

239 a higher blood pressure in patients with milder forms of CAH, i.e., I172N and NC groups (5, 26).  
240 Moreover, classic adult CAH males were recently reported to have lower blood pressure compared to  
241 healthy men (24). Mineralocorticoid replacement is generally mandatory in SW and is often  
242 recommended in SV cases to minimise the glucocorticoid doses (1-3), and it is sometimes used even  
243 in NC patients (4, 5, 8, 26). A more cautious approach to prescribing mineralocorticoids could  
244 possibly be employed, but this has to be investigated in studies where the prescribed doses of  
245 mineralocorticoids are known and, ultimately, in randomised controlled trials. Obesity was more  
246 pronounced among patients with the milder forms and this may contribute to the development of  
247 hypertension. One of the main risks of hypertension is stroke, and we did find an increased occurrence  
248 of stroke in the NC female group, but not in the other groups. It has been demonstrated that patients  
249 with classic CAH and severe mutations have reduced epinephrine production (null and I2splice),  
250 whereas those carrying the milder I172N had normal production (1, 5). It could be speculated that not  
251 only a later diagnosis of CAH (5, 26), but also differences in epinephrine secretion, could influence  
252 the cardiovascular risk profiles (5).

253 Another risk factor for stroke, atrial fibrillation, was increased in CAH individuals and in the  
254 I172N group, but this time only in males. Atrial fibrillation has never been studied in CAH before, but  
255 heart rates have been reported to be elevated (5, 29). Alcohol can precipitate atrial fibrillation and  
256 alcohol misuse was increased in these CAH males, as reported previously by our group (17); however,  
257 this was only significant in the I2 splice group. Thyrotoxicosis can also predispose to atrial fibrillation,  
258 and this risk was increased in CAH individuals. The frequency of thyrotoxicosis was extremely high  
259 compared to controls in null and NC males, while being only moderately raised in NC females. The  
260 prevalence of hypothyroidism was also elevated, especially in the male subgroups. However, thyroid  
261 disorders are generally more common in females, which may explain the lower OR in CAH females.  
262 Thyroid disorders have not been studied before in CAH. The main cause of both hyper- and  
263 hypothyroidism is autoimmunity and the question arises of whether there is an increased risk for  
264 autoimmune disorders in CAH. The gene responsible for the 21-hydroxylase enzyme, *CYP21A2*, and  
265 its pseudogene, *CYP21A1P*, is located in the HLA major histocompatibility complex on chromosome  
266 6p21.3, about 30 kb apart, next to the *C4B* and *C4A* genes, but there are also other genes involved in

267 the immune system located in the vicinity (30). A putative link is purely speculative but should be  
268 studied further.

269 We were able to show for the first time an increased frequency of venous thromboembolic  
270 events in CAH individuals. This could be expected, as both Cushing's syndrome and glucocorticoid  
271 use have been associated with venous thromboembolism due to a state of hypercoagulability (31).  
272 More liberal use of thrombosis prophylaxis may be warranted.

273 Patients born after the introduction of neonatal CAH screening seemed to be less affected than  
274 those born before, which may indicate a benefit of early diagnosis and/or more optimal corticosteroid  
275 replacement therapy in recent years. However, there was a difference in mean age of almost 26 years  
276 between the two groups. When stratifying the cohort into different age groups, all age groups were  
277 equally affected by any cardiovascular and metabolic disorder. However, the older age groups also had  
278 an increased risk of cardiovascular disease while the younger mainly were affected by obesity and  
279 thyrotoxicosis; females also had more hypertension and males hypothyroidism compared to controls.

280 The major limitations of this study are that all outcome data were derived from national  
281 registers, and the ICD coding may have been inadequate. A prerequisite for obtaining approval by the  
282 Ethics Committee was that all individuals included were anonymised to protect their privacy.  
283 Therefore, it was impossible to analyse the results on an individual level and compare them with  
284 medical files. There may be ascertainment bias as the CAH patients were more likely to be under  
285 intensive surveillance compared to controls, which may explain some of the differences, e.g. the  
286 observation of hypothyroidism and obesity. However, more severe conditions were presumably  
287 detected equally in patients and controls. Moreover, the number of patients with cardiovascular  
288 disease was low, in spite of the large number of included individuals with CAH due to the low median  
289 age of only 26 years, considering that most cardiovascular events occur in the middle and older age  
290 groups. Furthermore, the number of patients in the different severity subgroups was low and some of  
291 the ICD codes were used only occasionally. Moreover, the many different subgroup analyses  
292 performed will, by definition, give rise to some significant results by sheer chance. Hence, the results  
293 from the subgroup analysis must be interpreted with caution. However, the present study probably

294 underestimates the cardiovascular morbidity among patients with CAH as we have recently shown  
295 from the same cohort that this group died 6.5 years earlier compared to controls, mainly due to adrenal  
296 crisis (13). Thus, the CAH patients have not had the same risk of developing cardiovascular disease. In  
297 contrast, the strengths of this study are the unique national registry of CAH individuals covering  
298 almost all CAH patients diagnosed in Sweden, with most registered patients being both pheno- and  
299 genotyped, and the almost complete coverage of all discharge diagnoses according to ICD of both in-  
300 and outpatient care by the National Patient Register.

301 In conclusion, CAH was associated with excess cardiovascular and metabolic morbidity. Some  
302 subgroups seemed to be more affected. Regular follow-up is needed with lifestyle intervention to limit  
303 the onset of weight gain and obesity, screening for diabetes, other metabolic disorders and  
304 cardiovascular risk factor. Close monitoring of glucocorticoid doses is important.

## References

1. **Merke DP, Bornstein SR** 2005 Congenital adrenal hyperplasia. *Lancet* 365:2125-2136
2. **Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC** 2010 Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *The Journal of clinical endocrinology and metabolism* 95:4133-4160
3. **Falhammar H, Thoren M** 2012 Clinical outcomes in the management of congenital adrenal hyperplasia. *Endocrine* 41:355-373
4. **Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, Hagenfeldt K, Thoren M** 2007 Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *The Journal of clinical endocrinology and metabolism* 92:110-116
5. **Falhammar H, Filipsson Nystrom H, Wedell A, Thoren M** 2011 Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *European journal of endocrinology / European Federation of Endocrine Societies* 164:285-293
6. **Sartorato P, Zulian E, Benedini S, Mariniello B, Schiavi F, Bilora F, Pozzan G, Greggio N, Pagnan A, Mantero F, Scaroni C** 2007 Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *The Journal of clinical endocrinology and metabolism* 92:1015-1018
7. **Mooij CF, Kroese JM, Claahsen-van der Grinten HL, Tack CJ, Hermus AR** 2010 Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia? *Clinical endocrinology* 73:137-146
8. **Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ** 2010 Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. *The Journal of clinical endocrinology and metabolism* 95:5110-5121
9. **Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, Hagenfeldt K, Thoren M** 2009 Increased liver enzymes in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr J* 56:601-608
10. **Nermoen I, Bronstad I, Fougner KJ, Svartberg J, Oksnes M, Husebye ES, Lovas K** 2012 Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. *European journal of endocrinology / European Federation of Endocrine Societies* 167:507-516
11. **Amr NH, Ahmed AY, Ibrahim YA** 2014 Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia. *Journal of endocrinological investigation*
12. **Hagenfeldt K, Janson PO, Holmdahl G, Falhammar H, Filipsson H, Frisen L, Thoren M, Nordenskjold A** 2008 Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Hum Reprod* 23:1607-1613
13. **Falhammar H, Frisen L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjold A, Nordenstrom A** 2014 Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *The Journal of clinical endocrinology and metabolism*:jc20142957

14. **Grais IM, Sowers JR** 2014 Thyroid and the heart. *The American journal of medicine* 127:691-698
15. **Gidlöf S, Falhammar H, Thilén A, von Döbeln A, Ritzén M, Wedell A, Nordenström A** 2013 One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. *The Lancet Diabetes & Endocrinology* 1:35-43
16. **Falhammar H** 2014 Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status? *Endocrine* 47:308-314
17. **Falhammar H, Butwicka A, Landen M, Lichtenstein P, Nordenskjold A, Nordenstrom A, Frisen L** 2014 Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *The Journal of clinical endocrinology and metabolism* 99:E554-560
18. **Strandqvist A, Falhammar H, Lichtenstein P, Hirschberg AL, Wedell A, Norrby C, Nordenskjold A, Frisen L, Nordenstrom A** 2014 Suboptimal psychosocial outcomes in patients with congenital adrenal hyperplasia: epidemiological studies in a nonbiased national cohort in Sweden. *The Journal of clinical endocrinology and metabolism* 99:1425-1432
19. **Falhammar H, Filipsson Nystrom H, Wedell A, Brismar K, Thoren M** 2013 Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. *European journal of endocrinology / European Federation of Endocrine Societies* 168:331-341
20. **Bachelot A, Plu-Bureau G, Thibaud E, Laborde K, Pinto G, Samara D, Nihoul-Fekete C, Kuttent F, Polak M, Touraine P** 2007 Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Hormone research* 67:268-276
21. **Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, Hermus AR, Otten BJ** 2003 Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. *The Journal of clinical endocrinology and metabolism* 88:1036-1042
22. **Zhang HJ, Yang J, Zhang MN, Liu CQ, Xu M, Li XJ, Yang SY, Li XY** 2010 Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency. *Endocrine* 38:260-265
23. **Finkelstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, Merke DP** 2012 Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. *The Journal of clinical endocrinology and metabolism* 97:4429-4438
24. **Bouvattier C, Esterle L, Renoult-Pierre P, de la Perriere AB, Illouz F, Kerlan V, Pascal-Vigneron V, Drui D, Christin-Maitre S, Galland F, Brue T, Reznik Y, Schillo F, Pinsard D, Piguel X, Chabrier G, Decoudier B, Emy P, Tauveron I, Raffin-Sanson ML, Bertherat J, Kuhn JM, Caron P, Cartigny M, Chabre O, Dewailly D, Morel Y, Touraine P, Tardy-Guidollet V, Young J** 2015 Clinical outcome, hormonal status, gonadotrope axis and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. A French national survey. *The Journal of clinical endocrinology and metabolism*:jc20144124
25. **Hamada S, Chin K, Hitomi T, Oga T, Handa T, Tuboi T, Niimi A, Mishima M** 2012 Impact of nasal continuous positive airway pressure for congenital adrenal hyperplasia with obstructive sleep apnea and bruxism. *Sleep & breathing = Schlaf & Atmung* 16:11-15
26. **Williams RM, Deeb A, Ong KK, Bich W, Murgatroyd PR, Hughes IA, Acerini CL** 2010 Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. *Clinical endocrinology* 72:155-160



27. **Diamanti-Kandarakis E, Dunaif A** 2012 Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocrine reviews* 33:981-1030
28. **Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, Hagenfeldt K, Thoren M** 2007 Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. *The Journal of clinical endocrinology and metabolism* 92:4643-4649
29. **Mooij CF, Kroese JM, Sweep FC, Hermus AR, Tack CJ** 2011 Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile. *PloS one* 6:e24204
30. **White PC, Speiser PW** 2000 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocrine reviews* 21:245-291
31. **van Zaane B, Stuijver DJ, Squizzato A, Gerdes VE** 2013 Arterial and venous thrombosis in endocrine diseases. *Seminars in thrombosis and hemostasis* 39:489-495

**Table 1.** The discharge diagnoses from the National Patient Registry analysed according to ICDs for both in- and outpatient care.

	<b>Diagnosis</b>	<b>ICD 8</b>	<b>ICD 9</b>	<b>ICD 10</b>
1	Obesity	277	278	E66
2	Diabetes mellitus	250	250	E10, E11, E13
3	Type 1 and type 2 diabetes			E10 & E11
4	OSA	347.00, 780.60	347, 780F	G47
5	Hyperlipidaemia	272	272	E78
6	Hypertension	401	401, 405	I10, I15
7	Stroke <sup>§</sup>	430-436	430-436	I60-I64, G45
8	ACS	410,411	410,411	I20-I22
9	Cardiac arrest	427.98	427F	I46
10	Heart failure	427.00, 427.10	428	I50
11	Atrial fibrillation*	427.92	427D	I48
12	Heart block	427.20, 427.28	426	I44, I45
13	Aortic valve disease**	395	424B	I35
14	VTE	450, 451	415, 451	I26, I80
15	Cardiomyopathy	425	425	I42
16	Aortic aneurysm & dissection	441	441	I71
17	Pulmonary heart diseases	426	416	I27
18	Hypotension	458	458	I95
19	Thyrotoxicosis	242	242	E05
20	Hypothyroidism	244, 245	244, 245	E03, E06

\*includes atrial flutter. \*\*non-rheumatic. <sup>§</sup>includes transient cerebral ischaemic attack. ACS, acute

coronary syndrome, i.e. heart attack and unstable angina. VTE, venous thromboembolism. OSA, obstructive sleep apnoea, but also includes other occasional sleep disorders. Any cardiovascular and/or metabolic disorder was defined as no. 1–20, and any cardiovascular disease as no. 6–18.

**Table 2.** Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency, also divided into females and males, compared with age- and sex-matched controls (100 controls per case).

	CAH individuals	Controls	Odds ratio (95% CI)	CAH females	Controls females	Odds ratio (95% CI)	CAH males	Controls males	Odds ratio (95% CI)
n	588	58 800		335	33 500		253	25 300	
Any CVD & meta	99(16.8%)	3460(5.9%)	<b>3.9(3.1-5.0)</b>	62(18.5%)	3460(5.9%)	<b>4.4(3.2-6.0)</b>	37(14.6%)	1496(5.9%)	<b>3.3(2.3-4.9)</b>
Any CVD	44(7.5%)	2103(3.6%)	<b>2.7(1.9-3.9)</b>	30(9.0%)	1109(3.3%)	<b>3.9(2.5-6.1)</b>	14(5.5%)	1008(3.9%)	1.6(0.9-2.9)
Obesity	29(4.9%)	281(0.5%)	<b>10.9(7.4-16.2)</b>	18(5.4%)	170(0.5%)	<b>11.3(6.8-18.7)</b>	11(4.3%)	111(0.4%)	<b>10.4(5.5-19.5)</b>
Diabetes	16(2.7%)	741(1.3%)	<b>3.0(1.6-5.8)</b>	10(3.0%)	375(1.1%)	<b>4.0(1.8-9.1)</b>	6(2.4%)	366(1.4%)	2.1(0.7-6.1)
OSA	8(1.4%)	406(0.7%)	<b>2.0(1.0-4.1)</b>	3(0.9%)	154(0.5%)	2.0(0.6-6.2)	5(2.0%)	252(1.0%)	2.0(0.8-5.0)
Hyperlipidaemia	6(1.0%)	230(0.4%)	<b>2.8(1.2-6.5)</b>	3(0.9%)	110(0.3%)	2.9(0.9-9.5)	3(1.2%)	120(0.5%)	2.7(0.8-8.8)
Hypertension	23(3.9%)	1058(1.8%)	<b>2.6(1.6-4.2)</b>	18(5.4%)	582(1.7%)	<b>4.1(2.4-7.3)</b>	5(2.0%)	477(1.9%)	1.1(0.4-2.7)
Stroke <sup>s</sup>	5(0.9%)	423(0.7%)	1.2(0.5-3.1)	4(1.2%)	253(0.8%)	1.7(0.6-4.9)	1(0.4%)	170(0.7%)	0.6(0.1-4.3)
ACS	6(1.0%)	436(0.7%)	1.5(0.6-3.5)	2(0.6%)	198(0.6%)	1.0(0.2-4.4)	4(1.6%)	238(0.9%)	1.9(0.6-5.7)
Cardiac arrest	1(0.2%)	35(0.1%)	2.8(0.4-21.0)	0(0%)	17(0.1%)		1(0.4%)	18(0.1%)	<i>5.6(0.7-42.0)</i>
Heart failure	3(0.5%)	209(0.4%)	1.5(0.4-5.1)	2(0.6%)	109(0.3%)	2.0(0.4-9.3)	1(0.4%)	100(0.4%)	1.0(0.1-7.9)
Atrial fibrillation*	7(1.2%)	331(0.6%)	<b>2.3(1.0-5.2)</b>	3(0.9%)	156(0.5%)	2.1(0.6-7.1)	4(1.6%)	175(0.7%)	<i>2.5(0.9-7.4)</i>
Heart block	3(0.5%)	120(0.2%)	2.5(0.8-8.0)	1(0.3%)	56(0.2%)	1.8(0.2-13.1)	2(0.8%)	64(0.3%)	3.2(0.8-13.0)
Aortic valve dis**	2(0.3%)	101(0.2%)	2.0(0.5-8.3)	1(0.3%)	52(0.2%)	1.0(0.3-14.7)	1(0.4%)	49(0.2%)	2.1(0.3-15.4)
VTE	6(1.0%)	165(0.3%)	<b>3.8(1.6-8.7)</b>	5(1.5%)	106(0.3%)	<b>5.0(2.0-12.7)</b>	1(0.4%)	59(0.2%)	1.7(0.2-12.4)
Thyrotoxicosis	10(1.7%)	223(0.4%)	<b>4.7(2.4-8.9)</b>	7(2.1%)	204(0.6%)	<b>3.5(1.6-7.6)</b>	3(1.2%)	19(0.1%)	<b>15.8(4.7-53.4)</b>
Hypothyroidism	15(2.6%)	418(0.7%)	<b>3.7(2.2-6.3)</b>	8(2.4%)	362(1.1%)	<b>2.3(1.1-4.6)</b>	7(2.8%)	56(0.2%)	<b>12.9(5.8-28.7)</b>

CI, confidence interval. <sup>s</sup>Includes transient cerebral ischaemic attack. \*Includes atrial flutter. \*\*Non-rheumatic. CVD, cardiovascular disease. meta, metabolic

disorder. OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. **Bold**, P<0.05.

*Italic*, P=0.05–0.09. No odds ratio and CI are calculated when no patient had the condition.

**Table 3.** Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency divided into the three phenotypes, compared with age- and sex-matched controls (100 controls per case).

	SW			SV			NC		
	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)
	All	Females	Males	All	Females	Males	All	Females	Males
n	240	135	105	167	91	76	75	56	19
Any CVD & meta	<b>3.2(2.1-4.9)</b>	<b>2.4(1.3-4.5)</b>	<b>4.4(2.4-8.0)</b>	<b>2.9(1.8-4.6)</b>	<b>3.9(2.1-7.0)</b>	<i>1.9(0.9-4.0)</i>	<b>5.6(2.9-10.8)</b>	<b>5.9(2.9-12.3)</b>	<b>4.5(1.0-21.0)</b>
Any CVD	<b>2.7(1.4-5.3)</b>	2.1(0.8-6.0)	<b>3.4(1.4-8.2)</b>	<i>1.8(0.9-3.5)</i>	<b>3.3(1.5-7.6)</b>	0.9(0.3-2.5)	<b>2.9(1.0-8.3)</b>	<b>3.7(1.2-11.2)</b>	
Obesity	<b>10.9(5.8-20.7)</b>	<b>8.6(3.4-21.8)</b>	<b>14.1(5.8-34.4)</b>	<b>6.9(3.0-16.0)</b>	<b>5.9(1.8-19.3)</b>	<b>8.3(2.5-27.3)</b>	<b>17.1(5.7-51.8)</b>	<b>15.3(4.3-54.9)</b>	<b>25.0(2.8-224)</b>
Diabetes	1.8(0.2-13.2)		3.2(0.4-24.2)	<b>3.1(1.2-8.4)</b>	<b>6.2(1.8-21.5)</b>	1.6(0.4-7.5)	<b>4.1(1.2-13.7)</b>	<b>5.5(1.6-19.3)</b>	
OSA	0.8(0.1-5.8)	2.0(0.3-14.7)		<b>2.8(1.0-7.6)</b>	2.2(0.3-16.3)	<i>3.0(0.9-9.7)</i>	2.6(0.4-19.2)	3.3(0.4-24.7)	
Hyperlipidaemia	<b>6.2(1.4-27.3)</b>		<b>11.1(2.3-53.2)</b>	1.6(0.4-6.7)	2.2(0.3-16.7)	1.3(0.2-9.8)			
Hypertension	1.2(0.3-4.9)		2.6(0.6-11.2)	1.7(0.7-3.9)	<b>5.0(1.9-13.1)</b>	0.3(0.0-2.2)	2.8(0.8-10.5)	<i>3.2(0.8-12.6)</i>	
Stroke <sup>s</sup>				0.5(0.1-3.8)		0.8(0.1-6.3)	<b>5.8(1.1-30.8)</b>	<b>5.8(1.1-30.8)</b>	
ACS	<b>5.3(1.2-24.3)</b>		<b>9.9(2.0-50.1)</b>	1.4(0.4-4.9)	2.4(0.3-19.7)	1.1(0.2-5.2)			
Heart failure				2.3(0.5-10.8)	<i>6.3(0.8-48.4)</i>	1.3(0.2-10.9)	<i>8.0(0.7-92.8)</i>	<i>9.1(0.7-114)</i>	
Atrial fibrillation*	2.3(0.3-17.4)		3.8(0.5-29.6)	2.3(0.7-8.2)		<i>3.1(0.8-11.6)</i>	3.6(0.4-30.5)	4.3(0.5-38.5)	
Heart block				<i>3.9(0.9-16.4)</i>	4.7(0.6-35.5)	3.4(0.5-25.3)			
VTE	<b>10.5(3.1-35.3)</b>	<b>13.1(2.9-58.9)</b>	<i>7.4(0.9-59.0)</i>				<i>7.0(0.9-55.5)</i>	<b>8.9(1.1-74.7)</b>	
Thyrotoxicosis	<b>4.5(1.4-14.5)</b>	1.6(0.2-11.7)	<b>33.3(6.7-165)</b>				<b>12.3(4.1-36.9)</b>	<b>8.9(2.6-30.8)</b>	<b>326(12.8-&gt;1000)</b>
Hypothyroidism	2.2(0.7-7.1)	0.9(0.1-6.3)	<b>8.7(2.1-37.3)</b>	<b>3.4(1.2-9.3)</b>	1.9(0.5-8.0)	<b>11.9(2.6-53.7)</b>	<b>5.7(1.7-19.0)</b>	<i>3.7(0.9-16.5)</i>	<b>50.0(4.5-551)</b>

CI, confidence interval. <sup>s</sup>Includes transient cerebral ischaemic attack. \*Includes atrial flutter. CVD, cardiovascular disease. meta, metabolic disorder. OSA,

obstructive sleep apnoea. ACS, acute coronary syndrome, i.e. heart attack and unstable angina. VTE, venous thromboembolism. **Bold**, P<0.05. *Italic*, P=0.05-

0.07. No odds ratio and CI were calculated when no patient had the condition.

**Table 4.** Cardiovascular and metabolic disorders in CAH individuals constituting the four most common *CYP21A2* genotype groups compared with age- and sex-matched controls (100 controls per case). Severity of the genotype ranging from left to right.

	Null			I2 splice			I172N		
	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)
	All	Females	Males	All	Females	Males	All	Females	Males
n	100	59	41	122	67	55	130	72	58
Any CVD & meta	<b>5.1(2.8-9.5)</b>	2.4(0.8-6.8)	<b>10.9(4.8-24.7)</b>	1.9(0.9-3.8)	2.3(0.9-5.8)	1.4(0.4-4.7)	<b>3.4(2.1-5.6)</b>	<b>4.9(2.6-9.0)</b>	1.9(0.8-4.5)
Any CVD	<b>4.9(1.9-13.1)</b>	2.0(0.3-14.6)	<b>8.9(2.7-29.3)</b>	1.3(0.4-4.1)	1.6(0.4-6.8)	0.8(0.1-6.9)	<b>2.2(1.1-4.4)</b>	<b>3.8(1.6-8.8)</b>	1.1(0.4-3.4)
Obesity	<b>10.1(4.0-26.2)</b>	<b>6.5(1.5-27.9)</b>	<b>16.3(4.6-58.0)</b>	<b>8.2(2.9-23.3)</b>	<b>11.7(3.4-39.8)</b>	4.3(0.6-32.8)	<b>7.0(2.8-17.6)</b>	<b>7.0(2.1-23.1)</b>	<b>7.1(1.7-30.1)</b>
Diabetes				1.1(0.1-7.7)		2.3(0.3-16.8)	<b>3.7(1.4-10.2)</b>	<b>7.1(2.0-25.0)</b>	2.0(0.4-9.3)
OSA	1.9(0.3-14.3)	4.8(0.6-36.2)					2.7(0.8-8.6)	2.8(0.4-21.1)	2.6(0.6-10.9)
Hyperlipidaemia	<b>11.1(1.3-97.5)</b>		<b>18.1(1.7-188)</b>				1.9(0.4-8.0)	2.3(0.3-18.2)	1.6(0.2-12.1)
Hypertension	1.9(0.3-14.7)		3.5(0.4-29.1)				2.0(0.9-4.7)	<b>5.5(2.1-14.7)</b>	0.3(0.0-2.7)
Stroke <sup>§</sup>							0.5(0.1-4.1)		0.8(0.1-7.1)
ACS	<b>18.1(1.7-188)</b>		<b>34.6(2.1-579)</b>				1.6(0.5-5.8)	2.4(0.3-19.7)	1.4(0.3-6.5)
Heart failure							2.6(0.6-12.3)	6.8(0.9-52.0)	1.5(0.2-12.6)
Atrial fibrillation*				3.3(0.4-25.6)		6.1(0.7-50.8)	2.7(0.8-9.5)		<b>3.8(1.0-14.4)</b>
Heart block							<b>4.7(1.1-19.7)</b>	5.4(0.7-42.2)	<b>4.1(0.5-31.1)</b>
VTE	<b>10.5(1.3-86.6)</b>		<b>18.2(2.0-167)</b>	<b>12.5(2.8-56.6)</b>	<b>21.6(4.5-104)</b>				
Thyrototoxicosis	<b>8.8(2.0-39.0)</b>		<b>200(18.1-&gt;1000)</b>	2.7(0.4-20.5)	2.9(0.4-21.8)				
Hypothyroidism	2.0(0.3-14.9)		<b>14.3(1.8-116)</b>				<b>4.2(1.5-11.8)</b>	2.5(0.6-10.3)	<b>13.6(2.9-62.9)</b>

P30L males with odds ratio (95% CI): Any CV & metab **7.1(1.5-34.8)**; obesity **7.1(1.5-34.8)**; and OSA 7.6(0.9-63). Women with P30L genotype had none of the

studied disorders. CI, confidence interval. <sup>§</sup>Includes transient cerebral ischaemic attack. \*Includes atrial flutter. CVD, cardiovascular. meta, metabolic disorder.

OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. **Bold**, P<0.05. *Italic*,

P=0.05-0.07. No odds ratio and CI were calculated when no patient had the condition.

**Table 5.** Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency in different age groups, also divided into females and males, compared with their age- and sex-matched controls.

	0-19 years old			20-39 years old			40-92 years old		
	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)
	All	Females	Males	All	Females	Males	All	Females	Males
n	228	122	106	239	143	96	121	70	51
Any CVD & meta	<b>4.2(2.4-7.1)</b>	<b>3.7(1.7-8.1)</b>	<b>4.6(2.2-9.6)</b>	<b>3.7(2.5-5.4)</b>	<b>4.2(2.6-6.6)</b>	<b>3.0(1.5-5.8)</b>	<b>3.9(2.6-5.8)</b>	<b>4.9(2.9-8.3)</b>	<b>2.7(1.4-5.2)</b>
Any CVD	2.2(0.5-10.2)	2.9(0.4-21.6)	1.7(0.2-15.9)	<b>3.8(2.1-6.8)</b>	<b>6.0(3.1-11.5)</b>	1.3(0.3-5.3)	<b>2.2(1.4-3.6)</b>	<b>3.0(1.6-5.5)</b>	1.4(0.6-3.1)
Obesity	<b>12.6(6.4-24.8)</b>	<b>11.1(3.8-32.0)</b>	<b>13.9(5.8-33.4)</b>	<b>9.8(4.9-19.7)</b>	<b>9.3(3.9-21.8)</b>	<b>11.0(3.3-36.9)</b>	<b>11.3(5.8-22.3)</b>	<b>14.0(6.5-30.5)</b>	<b>6.5(1.5-27.7)</b>
Diabetes	2.3(0.6-9.2)	2.1(0.3-15.3)	2.5(0.3-18.0)	1.4(0.4-4.4)	2.5(0.8-8.3)		<b>2.9(1.5-5.6)</b>	<b>3.1(1.3-7.5)</b>	<b>2.7(1.0-7.1)</b>
OSA				1.6(0.4-6.4)	1.8(0.3-13.3)		<b>3.5(1.5-8.0)</b>	<i>3.5(0.8-14.7)</i>	<b>3.5(1.2-9.8)</b>
Hyperlipidaemia							<b>2.6(1.0-6.5)</b>	2.1(0.5-8.5)	<i>3.0(0.9-10.2)</i>
Hypertension	6.7(0.9-50.5)	<b>10.0(1.3-78.1)</b>		<b>5.3(2.4-11.8)</b>	<b>8.6(3.5-20.8)</b>		<b>1.9(1.0-3.4)</b>	<b>2.7(1.3-5.4)</b>	1.0(0.3-3.0)
Stroke <sup>§</sup>							1.1(0.4-3.2)	1.0(0.2-4.5)	0.6(0.1-5.0)
ACS							1.5(0.6-3.6)	2.4(0.3-19.7)	1.4(0.3-6.5)
Cardiac arrest							3.7(0.5-27.9)		<b>8.3(1.1-64.9)</b>
Heart failure							1.8(0.6-6.1)	2.3(0.5-11.0)	1.2(0.1-9.8)
Atrial fibrillation*				2.7(0.4-19.6)		4.1(0.6-30.8)	2.1(0.8-5.4)	2.6(0.7-9.3)	<b>3.8(1.0-14.4)</b>
Heart block	3.1(0.3-37.6)		3.7(0.3-49.2)				3.0(0.7-12.6)	3.2(0.4-23.8)	2.9(0.4-21.9)
Aortic valve dis**							2.9(0.7-12.2)	2.7(0.4-21.2)	3.0(0.4-23.1)
VTE				2.4(0.3-17.6)	3.7(0.5-27.2)		<b>4.6(1.8-11.5)</b>	6.0(2.1-17.4)	2.4(0.3-17.7)
Thyrotoxicosis	<b>28.6(5.9-138)</b>	<b>14.3(1.8-116)</b>	<b>201(18.0-&gt;1000)</b>	<b>5.1(2.0-12.6)</b>	<b>3.4(1.1-11.0)</b>	<b>16.4(3.7-73.4)</b>	<i>2.8(0.9-9.0)</i>	<i>2.9(0.9-9.5)</i>	
Hypothyroidism	2.1(0.5-9.6)		<b>7.6(1.4-43.1)</b>	<b>3.4(1.5-7.7)</b>	<b>3.1(1.3-7.7)</b>	<b>5.4(0.7-40.7)</b>	<b>4.8(2.2-10.6)</b>	2.2(0.7-7.1)	<b>26.9(8.4-86.1)</b>

CI, confidence interval. <sup>§</sup>Includes transient cerebral ischaemic attack. \*Includes atrial flutter. \*\*Non-rheumatic. CVD, cardiovascular disease. meta, metabolic

disorder. OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. **Bold**, P<0.05.

*Italic*, P=0.05-0.07. No odds ratio and CI were calculated when no patient had the condition.

